Immuno-pharmacokinetics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis Caused byLeishmania(Viannia) | Zendy

María Adelaida Gómez | Zendy; Adriavas | Zendy; Miguel Prieto | Zendy; Lina Giraldo-Parra | Zendy; Alexandra Cossio | Zendy; Neâl Alexander | Zendy; Nancy Gore Saravia | Zendy

Open Access

Immuno-pharmacokinetics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis Caused byLeishmania(Viannia)

Author(s) -

María Adelaida Gómez,

Adriavas,

Miguel Prieto,

Lina Giraldo-Parra,

Alexandra Cossio,

Neâl Alexander,

Nancy Gore Saravia

Publication year - 2020

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciaa1206

Subject(s) - meglumine antimoniate , leishmania , pharmacokinetics , cutaneous leishmaniasis , leishmaniasis , medicine , meglumine , pharmacology , dermatology , immunology , parasite hosting , computer science , world wide web , magnetic resonance imaging , radiology

Control of cutaneous leishmaniasis (CL) relies on chemotherapy, yet gaps in our understanding of the determinants of therapeutic outcome impede optimization of antileishmanial drug regimens. Pharmacodynamic (PD) parameters of antimicrobials are based on the relationship between drug concentrations/exposure and microbial kill. However, viable Leishmania persist in a high proportion of individuals despite clinical resolution, indicating that determinants other than parasite clearance are involved in drug efficacy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research